Researcher
An Wouters
- Research Expertise:* Coordinator of research lines focussing on targeted and combination therapy * Basic and translational research focussed on innovative combination strategies with targeted therapies for solid tumors and on unravelling resistance mechanisms
- Keywords:ONCOLOGY, TUMOR BIOLOGY, PRECLINICAL RESEARCH, CANCER THERAPY, Biomedical sciences (incl. biochemistry)
- Disciplines:Cancer biology, Cancer therapy
- Research techniques:* in vitro cell culture * cytotoxicity assays, radiation research, combination therapies * cellular and molecular techniques for detection of apoptosis, cell cycle distribution, protein expression, protein phosphorylation,...
- Users of research expertise:scientific researchers, teachers, physicians, people interested in cancer research
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Member
From1 Oct 2004 → 31 Dec 2018
Projects
1 - 10 of 22
- Targeting therapy-induced senescence in non-small cell lung cancer: development and optimization of a novel triple-step, senescence-focused treatment strategy.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Fundamental insights in the immunosuppressive metabolic effects of the hypoxic tumor microenvironment on natural killer cells in head and neck squamous cell carcinoma.From1 Nov 2023 → TodayFunding: FWO fellowships
- Metabolic rewiring of natural killer cells for enhanced functioning in the tumour microenvironment.From1 Sep 2023 → TodayFunding: IOF - technology concept exploration
- Targeting therapy-induced senescence in non-small cell lung cancer: development and optimization of a novel triple-step, senescence-focused treatment strategy.From1 Nov 2022 → 31 Oct 2023Funding: BOF - doctoral mandates
- High-end comprehensive GCxGC-QTOF-MS research facility for volatile and semivolatile compounds (GALILEO).From1 Jun 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- FLASH radiation therapy to improve the therapeutic management of breast cancer by reducing radiationinduced skin, soft tissue, lung and heart toxicities.From1 Apr 2022 → TodayFunding: Nonprofit institution or equivalents
- Combining targeted therapy and immunotherapy to improve survival and quality of life of head and neck cancer patients.From1 Mar 2021 → TodayFunding: Nonprofit institution or equivalents
- Gasping for air in the leukemic bone marrow: improving the functioning of natural killer cells in hypoxia.From23 Sep 2020 → 22 Sep 2021Funding: Foundations, funds and other with scientific goal
- Novel, rationally designed combination strategies, based on genomic and proteomic analyses, to enhance the response to cetuximab therapy in head and neck cancer.From1 Jan 2020 → 31 Dec 2020Funding: Nonprofit institution or equivalents
- Unraveling of the role and the regulation of hypoxia-inducible factors in natural killer cell functioning in hypoxic and stimulating environments.From1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
Publications
31 - 40 of 70
- Overcoming intrinsic and acquired cetuximab resistance in RAS wild-type colorectal cancer(2019)
Authors: Ines De Pauw, Filip Lardon, Jolien Van den Bossche, Hasan Baysal, Patrick Pauwels, Marc Peeters, Jan Vermorken, An Wouters
- Novel prognostic biomarkers and therapeutic targets for non-small cell lung cancer(2018)
Authors: An Wouters, Marc Peeters
Number of pages: 206 - Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade(2018)
Authors: Jorrit De Waele, Elly Marcq, Jonas Van Audenaerde, Jinthe Van Loenhout, Karen Zwaenepoel, Erik Van de Kelft, David Van der Planken, Tomas Menovsky, Johan Van den Bergh, Yannick Willemen, et al.
- Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy(2018)
Authors: Laure Sorber, An Wouters, Annelies J R Janssens, Birgitta Hiddinga, Patrick Pauwels, Christian Rolfo
Pages: 754 - 756 - Hypoxia-induced cisplatin resistance in non-small cell lung cancer cells is mediated by HIF-1 alpha and mutant p53 and can be overcome by induction of oxidative stress(2018)
Authors: Jorrit De Waele, Julie Jacobs, An Wouters, Marc Peeters, Christian Rolfo, Evelien Smits, Patrick Pauwels
- Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines(2018)
Authors: Ines De Pauw, Hasan Baysal, Erik Fransen, Patrick Pauwels, Marc Peeters, Jan Vermorken, An Wouters
Pages: 830 - 854 - Deep sequencing of the TP53 gene reveals a potential risk allele for nonsmall cell lung cancer and supports the negative prognostic value of TP53 variants(2017)
Authors: Christophe Deben, Jolien Van den Bossche, Nele Van Der Steen, An Wouters, Christophe Hermans, Julie Jacobs, Marc Peeters, Guy Van Camp, Christian Rolfo, Patrick Pauwels
- Dual targeting of epidermal growth factor receptor and HER3 by MEHD7945A as monotherapy or in combination with cisplatin partially overcomes cetuximab resistance in head and neck squamous cell carcinoma cell lines(2017)
Authors: Ines De Pauw, An Wouters, Jolien Van den Bossche, Hasan Baysal, Patrick Pauwels, Marc Peeters, Jan Vermorken, Filip Lardon
Pages: 229 - 238 - MDM2 SNP309 and SNP285 act as negative prognostic markers for non-small cell lung cancer adenocarcinoma patients(2017)
Authors: Julie Jacobs, An Wouters, Marc Peeters, Guy Van Camp, Christian Rolfo, Patrick Pauwels
Pages: 2154 - 2162 - Towards prognostic profiling of non-small cell lung cancer(2017)
Authors: Jolien Van den Bossche, Christophe Deben, Christophe Hermans, Ines De Pauw, Julie Jacobs, Jan Vermorken, Patrick Pauwels, Marc Peeters, An Wouters
Pages: 1441 - 1452